All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 186 points (1.2%) at 15,852 as of Wednesday, Aug. 26, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,634 issues advancing vs. 1,393 declining with 136 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is up 0.7%. Top gainers within the industry include

Merck

(

MRK

), up 2.7%,

Amgen

(

AMGN

), up 1.6%,

Allergan

(

AGN

), up 0.6% and

AbbVie

(

ABBV

), up 0.5%. On the negative front, top decliners within the industry include

Valeant Pharmaceuticals International

(

VRX

), down 0.6%, and

Eli Lilly and

(

LLY

), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Regeneron Pharmaceuticals

(

REGN

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $8.48 (1.7%) to $507.50 on average volume. Thus far, 410,202 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 726,900 shares. The stock has ranged in price between $506.45-$518.51 after having opened the day at $513.22 as compared to the previous trading day's close of $499.02.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $51.3 billion and is part of the health care sector. The company has a P/E ratio of 127.4, above the S&P 500 P/E ratio of 24.3. Shares are up 21.6% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Regeneron Pharmaceuticals a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Regeneron Pharmaceuticals

as a

buy

TheStreet Recommends

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Regeneron Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Biogen

(

BIIB

) is up $2.46 (0.9%) to $284.21 on average volume. Thus far, 1.6 million shares of Biogen exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $284.12-$291.33 after having opened the day at $290.10 as compared to the previous trading day's close of $281.74.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $65.5 billion and is part of the health care sector. The company has a P/E ratio of 18.8, below the S&P 500 P/E ratio of 24.3. Shares are down 17.0% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts who rate Biogen a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates

Biogen

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Biogen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Johnson & Johnson

(

JNJ

) is up $0.84 (0.9%) to $91.57 on heavy volume. Thus far, 6.1 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.6 million shares. The stock has ranged in price between $91.46-$93.48 after having opened the day at $92.91 as compared to the previous trading day's close of $90.73.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Johnson & Johnson has a market cap of $257.0 billion and is part of the health care sector. The company has a P/E ratio of 16.3, below the S&P 500 P/E ratio of 24.3. Shares are down 13.2% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Johnson & Johnson

as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Johnson & Johnson Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).